Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Closed

Thoracic Cancer

Learn More

To learn more, visit ClinicalTrials.Gov or contact Clinical Research at 864-560-6812.

Principal Investigator(s)

Vikas Dembla, MD

Sponsor(s)

AstraZeneca

Key Trial Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.
1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICFs and in the protocol.
2. Age ≥18 years at the time of screening (ICF1);
3. Histologically confirmed NSCLC with resectable stage II-III disease
4. Complete resection of the primary NSCLC
- EGFR and/or ALK mutant
- Mixed small cell and NSCLC histology
- History of allogeneic organ or bone marrow transplantation
- History of active primary immunodeficiency

Clinical Research Trials

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Key Trial Criteria

Key Inclusion Criteria

Key Exclusion Criteria